David Huang
Senior Director, Head of ADC Enabling Technologies OBI Pharma
David Teng-Yi Huang, Ph.D., is Senior Director of ADC Enabling Technologies at OBI Pharma, where he leads the development of proprietary ADC platforms. His expertise spans carbohydrate chemistry, glycoengineering, site-specific conjugation, and novel linker-payload design. He received his Ph.D. in Chemistry from National Tsing Hua University and trained in glycoscience at Academia Sinica.
Seminars
Thursday 11th June 2026
Reimagining ADC Design Through Enzymatic Conjugation: Enabling Site-Specific & Dual-Payload ADCs
9:00 am
- Analyze how GlycOBI® is a glycan site-specific conjugation platform enabling programmable DAR control, highlighting how precise glycan engineering supports homogeneous ADCs and tunable drug loading
- Assess how linker design and DAR tuning are key determinants of ADC stability and pharmacokinetics, with mechanistic insights into how linker architecture and DAR optimization jointly influence circulation stability and exposure
- Outline dual-payload ADC design principles, including the impact of distinct conjugation sites and payload release efficiencies, and a case study illustrating the rational design of a bispecific dual-payload ADC to overcome resistance mechanisms
